USPTO Examiner OUSPENSKI ILIA I - Art Unit 1644

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19352098PD-L1 ANALOG FUSION PROTEINS FOR ANTIGEN SPECIFIC IMMUNOTHERAPY AND METHODS OF USEOctober 2025February 2026Allow510NoNo
19208792ANTI-GDF15 ANTIBODY AND A DOSAGE REGIMEN FOR THE TREATMENT OF CANCERMay 2025October 2025Allow511NoNo
19193595CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALINGApril 2025March 2026Allow1020NoNo
19193629CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALINGApril 2025October 2025Allow520NoNo
19193652CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALINGApril 2025October 2025Allow610NoNo
19071424PD-L1 ANALOG FUSION PROTEINS FOR ANTIGEN SPECIFIC IMMUNOTHERAPY AND METHODS OF USEMarch 2025August 2025Allow610YesNo
19050008NK/MONOCYTE ENGAGERSFebruary 2025July 2025Allow621NoNo
18939460METHODS COMPRISING ONCOLYTIC VIRUSES EXPRESSING CD19T AND BISPECIFIC T CELL ENGAGERSNovember 2024February 2026Allow1511YesNo
18829057METHOD OF REDUCING BISPECIFIC T CELL ENGAGER OR CHIMERIC ANTIGEN RECEPTOR T CELL MEDIATED CYTOKINE RELEASE SYNDROME USING INTERLEUKINS-4, -10, OR A FUSION PROTEIN THEREOFSeptember 2024December 2025Allow1511NoNo
18731180CELL SIGNALING COMPLEXES AND USES THEREOFMay 2024December 2024Allow711YesNo
18651979ANTI-AGING SALMON ROE TRIPEPTIDE AND PREPARATION METHOD AND APPLICATION THEREOFMay 2024February 2025Allow1020NoNo
18690247ANTI-PD-1 IMMUNOGLOBULIN POLYPEPTIDES AND USES THEREOFMarch 2024May 2025Allow1401NoNo
18501884DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10November 2023February 2024Allow400NoNo
18501914DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10November 2023May 2024Allow710NoNo
18501856DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10November 2023February 2024Allow300NoNo
18501584DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10November 2023January 2024Allow300NoNo
18501762DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10November 2023December 2023Allow200NoNo
18501850DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10November 2023January 2024Allow300NoNo
18501581DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10November 2023January 2024Allow200NoNo
18501561DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10November 2023January 2024Allow200NoNo
18501571DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10November 2023August 2024Allow920NoNo
18345885CELLS HAVING SOLID TUMOR TARGETING BACKBONE AND USE THEREOFJune 2023September 2024Allow1411NoNo
18327127ANTI-BTN3A ANTIBODIES AND THEIR USE IN TREATING CANCER OR INFECTIOUS DISORDERSJune 2023December 2023Allow720NoNo
17915109MONOCLONAL ANTIBODY BINDING TO TIGIT ANTIGEN, PREPARATION METHOD AND USE THEREOFMarch 2023September 2023Allow1210NoNo
18042158Methods and Compositions for Diabetes Treatment and Beta-Cell RegenerationFebruary 2023January 2026Allow3510NoNo
18016352ANTI-CLAUDIN 18.2 ANTIBODY AND ANTIBODY-DRUG CONJUGATE THEREOFJanuary 2023December 2025Allow3510NoNo
18085632MULTI SUBUNIT PROTEIN MODULES, CELLS EXPRESSING SAME AND USES THEREOFDecember 2022March 2024Allow1511YesNo
18056681ANTI-CTLA4 Antibodies, Antibody Fragments, Their Immunoconjugates and Uses ThereofNovember 2022February 2026Allow3910NoNo
18052110ANTI-ICOS AGONIST ANTIBODIES AND USES THEREOFNovember 2022January 2026Allow3820NoNo
18052076CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALINGNovember 2022May 2024Abandon1810NoNo
18052099CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALINGNovember 2022September 2024Abandon2210NoNo
18051773TARGETED BINDING AGENTS AGAINST B7-H1November 2022March 2026Allow4001NoNo
17959065T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOFOctober 2022September 2025Abandon3510NoNo
17936062PROTEINS SPECIFIC FOR BAFF AND B7RP1 AND USES THEREOFSeptember 2022September 2025Allow3611NoNo
17932822ANTI-CD26 ANTIBODIES AND USES THEREOFSeptember 2022November 2025Allow3810NoNo
17822251CHIMERIC MOLECULES PROVIDING TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPYAugust 2022January 2023Allow500NoNo
17822054COMBINATION OF VACCINATION AND INHIBITION OF THE PD-1 PATHWAYAugust 2022June 2025Allow3410NoNo
17878667PD-1 Binding Proteins and Methods of Use ThereofAugust 2022September 2025Abandon3810NoNo
17796661ANTIBODY, RELATED USE, PHARMACEUTICAL COMPOSITION INCLUDING METHOD FOR DIAGNOSING FUNGAL INFECTIONS, FUNGAL INFECTION DIAGNOSIS KIT AND METHOD FOR TREATING FUNGAL INFECTIONSJuly 2022December 2025Allow4010NoNo
17870479ANTI-PD-L1 ANTIBODIES AND ANTI-PD-L1/IL10 FUSION PROTEINSJuly 2022July 2023Allow1211NoNo
17811489REGULATORY T CELL MEDIATOR PROTEINS AND USES THEREOFJuly 2022September 2025Abandon3801NoNo
17842540HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1)June 2022March 2026Abandon4511NoNo
17806187Reducing Systemic Regulatory T Cell Levels or Activity for Treatment of Disease and Injury of the CNSJune 2022July 2025Allow3710NoNo
17835936FUSION PROTEINS OF PD-1 AND 4-1BBJune 2022August 2025Allow3810NoNo
17831637CONSTRUCTION OF CHIMERIC ANTIGEN RECEPTOR TARGETING CD20 ANTIGEN AND ACTIVITY IDENTIFICATION OF ENGINEERED T CELLS THEREOFJune 2022August 2025Allow3910NoNo
17828513GENETICALLY ENGINEERED HEMATOPOIETIC STEM CELLS AND USES THEREOFMay 2022January 2026Allow4311NoNo
17825297MICROVASCULAR BLOOD FLOW DECREASING AGENT AND USE THEREOFMay 2022May 2025Allow3610NoNo
17750658Combined chimeric antigen receptor targeting CD19 and CD20 and application thereofMay 2022December 2022Allow710NoNo
17664589FLT3 LIGAND FUSION PROTEINS AND METHODS OF USEMay 2022August 2022Allow300NoNo
17776201TREATMENT OF FIBROSIS WITH COMBINED BLOCKADE OF IL-6 AND IMMUNE CHECKPOINTMay 2022February 2026Allow4510NoNo
17662518ANTI-PD-1 ANTIBODIES AND METHODS OF USE THEREOFMay 2022August 2025Abandon3901NoNo
17662606ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND METHODS OF USE THEREOFMay 2022June 2025Allow3700NoNo
17736917NOVEL CTLA4-IG IMMUNOADHESINSMay 2022August 2025Allow3910NoNo
17772631Methods of Treating Cancer with Anti-PD-1 AntibodiesApril 2022February 2026Abandon4610NoNo
17725199ANTI-PD-1 ANTIBODIES AND METHODS OF USE THEREOFApril 2022June 2025Abandon3810NoNo
17285184ANTI-L1CAM ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND CHIMERIC ANTIGEN RECEPTOR COMPRISING SAMEApril 2022February 2026Allow5811NoNo
17721647Combined chimeric antigen receptor targeting CD19 and CD20 and application thereofApril 2022April 2025Allow3610NoNo
17288187ANTI-CTLA4 Antibodies, Antibody Fragments, Their Immunoconjugates and Uses ThereofMarch 2022September 2022Allow1610NoNo
17760738ANTI-B7-H3 ANTIBODY AND APPLICATION THEREOFMarch 2022December 2025Abandon4510NoNo
17685056B7-H4 ANTIBODIES AND METHODS OF USE THEREOFMarch 2022March 2026Allow4820NoNo
17684205DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10March 2022November 2022Allow810NoNo
17684229DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10March 2022December 2024Allow3400NoNo
17684151DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10March 2022November 2022Allow910NoNo
17684290DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10March 2022November 2024Allow3300NoNo
17684243DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10March 2022December 2022Allow910NoNo
17684272DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10March 2022November 2022Allow910NoNo
17684106DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10March 2022October 2022Allow710YesNo
17677814CD80 and CD86 Binding Protein Compositions and Uses ThereofFebruary 2022June 2025Allow4010NoNo
17677283Anti-B7-H4 Antibodies and ImmunoconjugatesFebruary 2022December 2024Allow3400NoNo
17677795CD80 and CD86 Binding Protein Compositions and Uses ThereofFebruary 2022September 2024Allow3100NoNo
17668125DOSING REGIMEN OF AVELUMAB FOR THE TREATMENT OF CANCERFebruary 2022August 2025Abandon4210NoNo
17590918THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCERFebruary 2022February 2025Allow3610NoNo
17582839ANTI-CTLA-4 ANTIBODIES AND METHODS OF USE THEREOFJanuary 2022August 2025Allow4210NoNo
17571905ANTIBODIES WITH REDUCED IMMUNOGENICITYJanuary 2022January 2026Allow4811NoNo
17622923SEMAPHORIN 3A ANTIBODIES AND USES THEREOFDecember 2021August 2025Allow4411NoNo
17554926Antigen Binding Proteins that Bind PD-1December 2021August 2025Abandon4401NoNo
17547528Anti-B7-H4 Antibodies and ImmunoconjugatesDecember 2021June 2024Allow3100NoNo
17529711ANTI-VISTA ANTIBODIES AND FRAGMENTSNovember 2021August 2025Allow4510NoNo
17523702TREATMENT OF PD-L1-NEGATIVE MELANOMA USING AN ANTI-PD-1 ANTIBODY AND AN ANTI-CTLA-4 ANTIBODYNovember 2021August 2025Allow4510NoNo
17482138Antibody Therapeutics that Bind CTLA4September 2021September 2025Abandon4811NoNo
17478587ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOFSeptember 2021October 2025Abandon4911NoNo
17475766COMBINED CHIMERIC ANTIGEN RECEPTOR TARGETING CD19 AND CD20 AND APPLICATION THEREOFSeptember 2021February 2022Allow510NoNo
17474702Combination Immunotherapy For The Treatment of CancerSeptember 2021October 2024Abandon3710NoNo
17469359ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1September 2021December 2024Abandon4010NoNo
17469708PROTEIN M FUSION PROTEINS AND USESSeptember 2021June 2022Allow911YesNo
17412614ICOS BINDING PROTEINSAugust 2021December 2024Abandon4010NoNo
17409118METHODS FOR UPREGULATING IMMUNE RESPONSES USING COMBINATIONS OF ANTI-RGMb AND ANTI-PD-1 AGENTSAugust 2021July 2024Allow3510NoNo
17407941METHODS OF REDUCING LIVER PD-1-EXPRESSING CD8+ T CELLS USING PD-1 FC FUSION PROTEINS THAT BIND FC RECEPTORSAugust 2021April 2025Abandon4401NoNo
17402768VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCERAugust 2021April 2025Abandon4410NoNo
17399829HUMAN ANTIBODIES TO PD-L1August 2021March 2024Abandon3110NoNo
17444519USE OF THE CD2 SIGNALING DOMAIN IN SECOND-GENERATION CHIMERIC ANTIGEN RECEPTORSAugust 2021October 2024Allow3920NoNo
17428214CAR LIBRARY AND scFv MANUFACTURING METHODAugust 2021November 2024Allow3911YesNo
17385636TREATMENT OF LUNG CANCER USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-CTLA-4 ANTIBODYJuly 2021February 2025Allow4210NoNo
17424484LEPTIN IMMUNOGENS, HYBRIDOMA CELLS, MONOCLONAL ANTIBODIES, POLYCLONAL ANTIBODIES AND USE THEREOFJuly 2021February 2025Allow4311NoNo
17373965BINDING MOLECULES TO THE HUMAN OX40 RECEPTORJuly 2021March 2024Abandon3210NoNo
17372208TREATMENT OF RENAL CELL CARCINOMAJuly 2021July 2024Allow3621NoNo
17367133METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORSJuly 2021February 2022Allow710NoNo
17367094METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORSJuly 2021February 2022Allow810NoNo
17366878BISPECIFIC ANTIBODYJuly 2021February 2024Allow3111NoNo
17361393TREATMENT OF AUTOIMMUNE DISORDERS WITH CD154 ANTIBODIESJune 2021September 2023Allow2720NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner OUSPENSKI, ILIA I.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
2
Examiner Affirmed
2
(100.0%)
Examiner Reversed
0
(0.0%)
Reversal Percentile
0.7%
Lower than average

What This Means

With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
87
Allowed After Appeal Filing
20
(23.0%)
Not Allowed After Appeal Filing
67
(77.0%)
Filing Benefit Percentile
30.7%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 23.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner OUSPENSKI, ILIA I - Prosecution Strategy Guide

Executive Summary

Examiner OUSPENSKI, ILIA I works in Art Unit 1644 and has examined 1,379 patent applications in our dataset. With an allowance rate of 70.6%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 31 months.

Allowance Patterns

Examiner OUSPENSKI, ILIA I's allowance rate of 70.6% places them in the 33% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by OUSPENSKI, ILIA I receive 1.51 office actions before reaching final disposition. This places the examiner in the 27% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by OUSPENSKI, ILIA I is 31 months. This places the examiner in the 54% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +28.8% benefit to allowance rate for applications examined by OUSPENSKI, ILIA I. This interview benefit is in the 77% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 36.0% of applications are subsequently allowed. This success rate is in the 81% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 69.2% of cases where such amendments are filed. This entry rate is in the 91% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 50.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 42% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 96.8% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 93.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 40.5% are granted (fully or in part). This grant rate is in the 31% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 6.7% of allowed cases (in the 89% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 6.6% of allowed cases (in the 84% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • RCEs are effective: This examiner has a high allowance rate after RCE compared to others. If you receive a final rejection and have substantive amendments or arguments, an RCE is likely to be successful.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.